Business Insider
My Markets Watchlist
Markets Stocks

Abbott Laboratories Stock , ABT

132.26 -1.74 -1.30%
03:59:59 PM EDT 6/17/2025 BTT
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Monday 06/16/2025 the closing price of the Abbott Laboratories share was $134.00 on BTT. Compared to the opening price on Monday 06/16/2025 on BTT of $136.47, this is a drop of 1.84%. Abbott Laboratories's market capitalization is $190.48 B by 1.74 B shares outstanding.
Is Abbott Laboratories stock a Buy, Sell or Hold? Abbott Laboratories stock has received a consensus rating of buy. The average rating score is Aa3 and is based on 34 buy ratings, 5 hold ratings, and 0 sell ratings.
What was the 52-week low for Abbott Laboratories stock? The low in the last 52 weeks of Abbott Laboratories stock was 97.90. According to the current price, Abbott Laboratories is 135.10% away from the 52-week low.
What was the 52-week high for Abbott Laboratories stock? The high in the last 52 weeks of Abbott Laboratories stock was 141.16. According to the current price, Abbott Laboratories is 93.70% away from the 52-week high.
What are analysts forecasts for Abbott Laboratories stock? The 39 analysts offering price forecasts for Abbott Laboratories have a median target of 132.92, with a high estimate of 160.00 and a low estimate of 107.00. The median estimate represents a 99.50 difference from the last price of 132.26.

Abbott Laboratories Stock Snapshot

126.49
Bid
100.00
Bid Size
134.01
Ask
2.00
Ask Size
6/17/2025
Date
3:59 PM
Time
210,178.00
Volume
134.00
Prev. Close
134.24
Open
230.31 B
Market Cap in USD
1.74 B
Number of Shares
1.74 B
Total Number of Shares
132.16
Day Low
134.24
Day High
132.26
97.90
52 Week Low
141.16
52 Week High
132.26
2.24
Dividend in USD
1.98
Dividend Yield
14.81
P/E Ratio
99.33
Free Float in %
7.64
EPS in USD
27.52
Book Value per Share in USD
4.90
Cash Flow per Share in USD

Historical Prices for Abbott Laboratories

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Abbott Laboratories Analyst Data

Total Analysts: 39
Buy Ratings: 34 Neutral Ratings: 5 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 107.00 Median: 132.92 Highest: 160.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

Abbott Laboratories Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
04/17/25 Raymond James Financial, Inc.
Maintained Buy $142
04/17/25 Piper Sandler
Maintained Buy $145
04/17/25 RBC Capital Markets
Maintained Buy $145
04/17/25 Wells Fargo & Co
Maintained Buy $147
04/17/25 Morgan Stanley
Maintained Hold $127
04/17/25 Barclays Capital
Maintained Buy $159
04/17/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $145
04/17/25 Jefferies & Company Inc.
Maintained Hold $137
03/10/25 Bank of America Merrill Lynch
Maintained Buy $150
03/04/25 Citigroup Corp.
Maintained Buy $160
03/04/25 Goldman Sachs
Maintained Buy $154
01/27/25 Barclays Capital
Maintained Buy $158
01/23/25 RBC Capital Markets
Maintained Buy $135
01/23/25 Wells Fargo & Co
Maintained Buy $136
01/23/25 Stifel, Nicolaus & Co., Inc.
Maintained Buy $135
01/23/25 UBS
Maintained Buy $148
07/29/24 Barclays Capital
Maintained Buy $143
07/02/24 Evercore
Maintained Buy $120
06/04/24 RBC Capital Markets
Maintained Buy $125
05/30/24 Goldman Sachs
Maintained Buy $121
05/22/24 Citigroup Corp.
Maintained Buy $119
04/22/24 Barclays Capital
Maintained Buy $140
04/18/24 RBC Capital Markets
Maintained Buy $125
04/04/24 Evercore
Maintained Buy $125
04/03/24 Citigroup Corp.
Maintained Buy $128
02/14/24 RBC Capital Markets
Maintained Buy $128
01/26/24 Barclays Capital
Maintained Buy $141
01/25/24 Citigroup Corp.
Maintained Buy $126
01/25/24 RBC Capital Markets
Maintained Buy $128
01/25/24 Raymond James Financial, Inc.
Maintained Buy $127
01/11/24 RBC Capital Markets
Maintained Buy $128
01/03/24 Raymond James Financial, Inc.
Maintained Buy $124
12/13/23 Wells Fargo & Co
Maintained Buy $121
10/19/23 Morgan Stanley
Maintained Hold $107
10/19/23 Wells Fargo & Co
Maintained Buy $116
10/19/23 Raymond James Financial, Inc.
Maintained Buy $110
07/24/23 Barclays Capital
Maintained Buy $132
07/21/23 Morgan Stanley
Maintained Hold $112
07/21/23 Mizuho
Maintained Hold $115
07/21/23 Wolfe Research
Upgraded to Hold

Abbott Laboratories Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 44,655 48,065 51,645 55,547 59,861
Dividend 2.38 2.47 2.67 3.15 -
Dividend Yield (in %) 1.77 % 1.84 % 1.99 % 2.35 % -
EPS 5.16 5.69 6.28 6.89 7.57
P/E Ratio 25.97 23.57 21.35 19.45 17.70
EBIT 10,479 11,596 12,760 14,016 15,473
EBITDA 11,970 12,990 14,353 15,418 15,971
Net Profit 9,029 9,905 10,889 11,949 13,188
Net Profit Adjusted 9,029 9,905 10,889 11,949 13,188
Pre-Tax Profit 10,826 11,865 13,029 14,297 15,801
Pre-Tax Profit Reported 8,727 9,878 11,234 13,119 -
EPS (Non-GAAP) ex. SOE 5.10 5.60 6.20 - -
EPS (GAAP) 4.03 4.63 5.28 6.15 -
Gross Income 25,230 27,312 29,365 32,000 34,861
Cash Flow from Investing -2,054 -2,115 -2,182 -1,941 -2,004
Cash Flow from Operations 10,967 11,366 12,675 14,738 15,985
Cash Flow from Financing -7,238 -10,431 -8,384 -7,526 -7,961
Cash Flow per Share 6.09 6.34 6.99 - -
Free Cash Flow 8,124 9,092 9,850 11,349 -
Free Cash Flow per Share - - - - -
Book Value per Share 28.34 29.67 31.50 - -
Net Debt 2,856 -22 -3,606 -10,974 -
Research & Development Exp. 2,833 3,016 3,226 3,404 3,659
Capital Expenditure 2,196 2,263 2,412 2,089 2,004
Selling, General & Admin. Exp. 12,081 12,856 13,661 14,584 15,733
Shareholder’s Equity 50,120 51,692 54,468 66,255 72,932
Total Assets 84,020 83,676 86,489 98,170 105,390
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 22 22 24 24
Average Estimate - 1.253 USD 1.339 USD 5.161 USD 5.686 USD
Year Ago - 0.744 USD 0.943 USD 7.673 USD -
Publish Date - - - - -
Revenue Estimates
No. of Analysts - 23 23 25 25
Average Estimate - 11,058 USD 11,392 USD 44,655 USD 48,065 USD
Year Ago - 10,377 USD 10,635 USD 41,950 USD -
Publish Date - - - - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Sales 41,950.00 40,109.00 43,653.00 43,075.00 34,608.00 31,904.00 30,578.00
Change of sales in % 4.59 -8.12 1.34 24.47 8.48 4.34 11.64
Gross profit on sales 21,325.00 20,037.00 22,323.00 23,214.00 17,377.00 16,693.00 15,823.00
Gross profit on sales change in % 6.43 -10.24 -3.84 33.59 4.10 5.50 20.44
Operating income 6,851.00 6,435.00 8,362.00 9,200.00 5,291.00 4,591.00 3,844.00
Operating income change in % 6.46 -23.04 -9.11 73.88 15.25 19.43 79.96
Income before tax 7,013.00 6,664.00 8,306.00 8,211.00 4,968.00 4,077.00 2,873.00
Income before tax change in % 5.24 -19.77 1.16 65.28 21.85 41.91 28.78
Income after tax 13,351.00 5,701.00 6,905.00 7,042.00 4,449.00 3,666.00 2,319.00
Income after tax change in % 134.19 -17.44 -1.95 58.28 21.36 58.09 574.13

Balance Sheet in Mio. USD

2024 2023 2022 2021 2020 2019 2018
Total liabilities 33,513.00 34,387.00 37,533.00 39,172.00 39,545.00 36,586.00 36,451.00
Long-term liabilities per share 11.18 11.85 12.69 14.78 15.60 14.59 15.63
Equity 47,901.00 38,827.00 36,905.00 36,024.00 33,003.00 31,301.00 30,722.00
Equity change in % 23.47 5.23 2.47 9.21 5.46 1.85 -1.21
Balance sheet total 81,414.00 73,214.00 74,438.00 75,196.00 72,548.00 67,887.00 67,173.00
Balance sheet total change in % 11.20 -1.64 -1.01 3.65 6.87 1.06 -11.90

Key Data in USD

2024 2023 2022 2021 2020 2019 2018
Sales per share 24.00 22.93 24.75 24.08 19.38 17.91 17.28
P/E ratio (year end quote, basic EPS) 14.81 33.77 28.05 35.75 43.72 42.20 54.41
P/E ratio (year end quote, diluted EPS) 14.81 33.77 28.05 35.75 43.72 42.20 54.41
Dividend yield in % 1.98 1.89 1.75 1.29 1.40 1.52 1.60
Equity ratio in % 58.84 53.03 49.58 47.91 45.49 46.11 45.74
Debt ratio in % 41.16 46.97 50.42 52.09 54.51 53.89 54.26

Abbott Laboratories Insider Activity

Name Date shares traded shares held Price type (sell/buy) option
Blount Sally E. 04/29/2025 2,600.00 34,058.00 129.66 Sell No
Alpern Robert J 04/24/2025 1,635.00 40,798.00 n/a Buy No
McDew Darren W 04/24/2025 1,635.00 10,392.00 n/a Buy No
Gonzalez Patricia Paola 04/24/2025 1,635.00 6,919.00 n/a Buy No
O'Grady Michael 04/24/2025 1,635.00 5,317.00 n/a Buy No
Stratton John G 04/24/2025 1,635.00 19,033.00 n/a Buy No
Roman Michael F 04/24/2025 1,635.00 8,478.00 n/a Buy No
McKinstry Nancy 04/24/2025 1,635.00 38,724.00 n/a Buy No
Kumbier Michelle 04/24/2025 1,635.00 15,714.00 n/a Buy No
Blount Sally E. 04/24/2025 1,635.00 36,658.00 n/a Buy No
STARKS DANIEL J 04/24/2025 1,635.00 6,728,817.00 n/a Buy No
Babineaux-Fontenot Claire 04/24/2025 1,635.00 5,317.00 n/a Buy No
MCCOY JOHN A. JR. 03/02/2025 562.00 21,061.00 138.17 Sell No
Moreland Mary K 03/02/2025 791.00 95,583.00 138.17 Sell No
Ford Robert B 02/27/2025 31,651.00 253,305.00 135.87 Sell No
Boudreau Philip P 02/27/2025 4,908.00 56,553.00 135.87 Sell No
MCCOY JOHN A. JR. 02/27/2025 1,096.00 21,623.00 135.87 Sell No
Moreland Mary K 02/27/2025 5,598.00 96,374.00 135.87 Sell No
Boudreau Philip P 02/24/2025 22,495.00 61,461.00 n/a Buy No
Morrone Louis H. 02/24/2025 10,232.00 72,375.00 n/a Buy No
MCCOY JOHN A. JR. 02/24/2025 4,038.00 22,719.00 n/a Buy No
ALLEN HUBERT L 02/24/2025 15,475.00 200,281.00 n/a Buy No
Wainer Andrea F 02/24/2025 12,278.00 82,643.00 n/a Buy No
Moreland Mary K 02/24/2025 10,712.00 101,972.00 n/a Buy No
Ford Robert B 02/04/2025 285,388.00 220,059.00 131.17 Sell No

Abbott Laboratories Dividend Calendar

Date Name Dividend *yield Currency
2024 Abbott Laboratories 2.24 1.98 USD
2023 Abbott Laboratories 2.08 1.89 USD
2022 Abbott Laboratories 1.92 1.75 USD
2021 Abbott Laboratories 1.82 1.29 USD
2020 Abbott Laboratories 1.53 1.40 USD
2019 Abbott Laboratories 1.32 1.52 USD
2018 Abbott Laboratories 1.16 1.60 USD
2017 Abbott Laboratories 1.08 1.88 USD
2016 Abbott Laboratories 1.05 2.72 USD
2015 Abbott Laboratories 0.98 2.18 USD
2014 Abbott Laboratories 0.90 2.00 USD
2013 Abbott Laboratories 0.64 1.67 USD
2012 Abbott Laboratories 1.67 2.55 USD
2011 Abbott Laboratories 1.92 3.41 USD
2010 Abbott Laboratories 1.76 3.67 USD
2009 Abbott Laboratories 1.60 2.96 USD
2008 Abbott Laboratories 1.44 2.70 USD
2007 Abbott Laboratories 1.30 2.32 USD
2006 Abbott Laboratories 1.18 2.42 USD
2005 Abbott Laboratories 1.10 2.79 USD
2004 Abbott Laboratories 1.04 2.23 USD
2003 Abbott Laboratories 0.98 2.10 USD
2002 Abbott Laboratories 0.94 2.35 USD
2001 Abbott Laboratories 0.84 1.51 USD
2000 Abbott Laboratories 0.76 1.55 USD
1999 Abbott Laboratories 0.68 1.87 USD
*Yield of the Respective Date

Abbott Laboratories Calendar

Event Estimate Info Date

Abbott Laboratories Past Events

Event Actual EPS Info Date

Abbott Laboratories Profile

Abbott Laboratories engages in the discovery, development, manufacture, and sale of healthcare products. It operates through the following segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, clinics, physicians' offices, retailers, government agencies, and alternate care testing sites. The Nutritional Products segment caters to the worldwide sales of pediatric and adult nutritional products. The Medical Devices segment includes a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care and continuous glucose monitoring products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
2
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Abbott Laboratories Management

Name Job
Robert B. Ford Chairman, President & Chief Executive Officer
Gene Huang Chief Economist & Vice President
Philip P. Boudreau Chief Financial Officer & Executive VP-Finance
Sabina Ewing Chief Information Officer
Mary K. Moreland Executive Vice President-Human Resources
Daniel Gesua Sive Salvadori Executive Vice President-Nutritional Products
Lisa D. Earnhardt Group President-Medical Devices & Executive VP
Sally E. Blount Independent Director
Robert J. Alpern Independent Director
Michael F. Roman Independent Director
Michelle A. Kumbier Independent Director
Daniel J. Starks Independent Director
Darren W. McDew Independent Director
Michael G. O'Grady Independent Director
Claire L. Babineaux-Fontenot Independent Director
John G. Stratton Independent Director
Paola Gonzalez Independent Director
Nancy McKinstry Lead Independent Director
Jim Leffelman Manager-Expense Reporting
Karen Wong Chayavirabood Regional Director-Asia
Hubert L. Allen Secretary, Executive VP & General Counsel
Melissa Brotz Senior VP-Global Marketing & External Affairs
Scott Leinenweber Senior VP-Licensing, Acquisitions & Ventures
Scott J. House Senior VP-Regulatory & Engineering Services
Randel William Woodgrift Senior Vice President-Cardiac Rhythm Management
Elizabeth Cushman Senior Vice President-Legal
Alison Davies Treasurer & Vice President
Kathryn S. Collins Vice President-Commercial Legal Operations
John A. McCoy Vice President-Finance & Controller